The impact of genetic factors on response to anaesthetics

Advances in Medical Sciences

Volumn 58, Issue 1, 2013, Pages 9-14

  Mikstacki, A ^a   Skrzypczak Zielinska, M ^b   Tamowicz, B ^a   Zakerska Banaszak, O ^c,d   Szalata, M ^b,c   Slomski, R ^b,c  

^a Regional Hospital   (Poland)

^b INSTITUTE OF HUMAN GENETICS   (Poland)

^c POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

^d ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

anaesthesia; genes; pharmacogenetics; propofol; sevoflurane

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; DESFLURANE; GLUCURONOSYLTRANSFERASE 1A9; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; HEXAFLUORO 2 PROPANOL; IONOTROPIC RECEPTOR; ISOFLURANE; PROPOFOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SEVOFLURANE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1;

APNEA; ARTICLE; BIOTRANSFORMATION; CARBON DIOXIDE ABSORBENT; CHEMICAL COMPOSITION; CODON; COMPETITIVE INHIBITION; CONDITIONED REFLEX; DEPRESSED BLOOD PRESSURE; DRUG METABOLISM; ENZYME ACTIVITY; GENERAL ANESTHESIA; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HALLUCINATION; HAPLOTYPE MAP; HEREDITY; HUMAN; HYPERVENTILATION; LIVER BLOOD FLOW; LIVER CELL; MOLECULAR WEIGHT; MUCOSA; NERVE CONDUCTION; PHARMACOGENETICS; PHARMACOGENOMICS; PROMOTER REGION; PROTEIN EXPRESSION; RISK REDUCTION; STRUCTURE ACTIVITY RELATION; TREMOR; VISUAL DISORDER;

EID: 84886449774     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0065-z     Document Type: Review

References (43)

1. Simpson NE, Kalow W. The "Silent" Gene For Serum Cholinesterase. Am J Hum Genet. 1964 Jun;16:180-8.
2. Kalow W. Pharmacogenetics and Anesthesia. Anesthesiology. 1964 May-Jun;25:377-87.
3. Klinger W. Biotransformation of drugs and other xenobiotics during postnatal development. Pharmacol Ther. 1982;16(3):377-429. (Pubitemid 12065503)
4. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004 Oct 21;431(7011):931-45.
5. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007 Oct 18;449(7164):851-861.
6. Smith I, Nathanson M, White PF. Sevoflurane-a long-awaited volatile anaesthetic. Br J Anaesth. 1996 Mar;76(3):435-45.
7. Watson KR, Shah MV. Clinical comparison of 'single agent' anaesthesia with sevoflurane versus target controlled infusion of propofol. Br J Anaesth. 2000 Oct;85(4):541-6.
8. Restrepo JG, Garcia-Martín E, Martínez C, Agúndez JA. Polymorphic drug metabolism in anaesthesia. Curr Drug Metab. 2009 Mar;10(3):236-46.
9. Fudickar A, Bein B. Propofol infusion syndrome: update of clinical manifestation and pathophysiology. Minerva Anestesiol. 2009 May;75(5):339-44.
10. Ingelman-Sundberg M. Polymorphism of cytochrome P450 and xenobiotic toxicity. Toxicology. 2002 Dec 27;181-182:447-52. (Pubitemid 36015735)
11. Landau R. Pharmacogenetics: implications for obstetric anesthesia. Int J Obstet Anesth. 2005 Oct;14(4):316-23. (Pubitemid 41411918)
12. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807. (Pubitemid 23296712)
13. Gentz BA, Malan TP Jr. Renal toxicity with sevoflurane: a storm in a teacup Drugs. 2001;61(15):2155-62. (Pubitemid 34074798)
14. Watanabe J, Hayashi S, Nakachi K, Imai K, Suda Y, Sekine T, Kawajiri K. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res. 1990 Dec 11;18(23):7194.
15. Hu Y, Oscarson M, Johansson I, Yue QY, Dahl ML, Tabone M, Arincò S, Albano E, Ingelman-Sundberg M. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol Pharmacol. 1997 Mar;51(3):370-6. (Pubitemid 27118471)
16. Preissner S, Kroll K, Dunkel M, Goldsobel G, Kuzmann D, Senger S, Günther S, Winnenburg R, Schroeder M, Preissner R. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43.
17. Kharasch ED, Hankins DC, Thummel KE. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
18. Kaymak C, Karahalil B, Ozcan NN, Oztuna D. Association between GSTP1 gene polymorphism and serum alpha-GST concentrations undergoing sevoflurane anaesthesia. Eur J Anaesthesiol. 2008 Mar;25(3):193-9. (Pubitemid 351170381)
19. Vanlersberghe C, Camu F. Propofol. Handb Exp Pharmacol. 2008;(182):227-52.
20. Yamanaka H, Nakajima M, Katoh M, Hara Y, Tachibana O, Yamashita J, McLeod HL, Yokoi T. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A922) and its effects on the transcriptional activity. Pharmacogenetics. 2004 May;14(5):329-32. (Pubitemid 38638920)
21. Loryan I, Lindqvist M, Johansson I, Hiratsuka M, van der Heiden I, van Schaik RH, Jakobsson J, Ingelman-Sundberg M. Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur J Clin Pharmacol. 2012 Apr;68(4):397-406.
22. Guitton J, Buronfosse T, Desage M, Flinois JP, Perdrix JP, Brazier JL, Beaune P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95. (Pubitemid 28282553)
23. Franks NP. Molecular targets underlying general anaesthesia. Br J Pharmacol. 2006 Jan;147 Suppl 1:S72-81. (Pubitemid 43077264)
24. Davies PA, Hanna MC, Hales TG, Kirknrss EF. Insensitivity to anaesthetic agents conferred by a class of GABA (A) receptor subunit. Nature. 1997 Feb 27;385(6619):820-3. (Pubitemid 27106071)
25. Bali M, Akabas MH. Defining the propofol binding site location on the GABA A receptor. Mol Pharmacol. 2004 Jan;65(1):68-76. (Pubitemid 38113887)
26. Krasowski MD, Koltchine VV, Rick CE, Ye Q, Finn SE, Harrison NL. Propofol and other intravenous anesthetics have sites of action on the gamma-aminobutyric acid type A receptor distinct from that for isoflurane. Mol Pharmacol. 1998 Mar;53(3):530-8. (Pubitemid 28162877)
27. Tsang SY, Ng SK, Xu Z, Xue H. The evolution of GABA A receptor-like genes. Mol Biol Evol. 2007 Feb;24(2):599-610.
28. Richardson JE, Garcia PS, O'Toole KK, Derry JM, Bell SV, Jenkins A. A conserved tyrosine in the beta2 subunit M4 segment is a determinant of gamma-aminobutyric acid type A receptor sensitivity to propofol. Anesthesiology. 2007 Sep;107(3):412-8. (Pubitemid 47329539)
29. Iohom G, Ni Chonghaile M, O'Brien JK, Cunningham AJ, Fitzgerald DF, Shields DC. An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. Eur J Anaesthesiol. 2007 Nov;24(11):912-9. (Pubitemid 47548626)
30. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci. 1991 Mar;12(3):102-7.
31. Searle R, Hopkins PM. Pharmacogenomic variability and anaesthesia. Br J Anaesth. 2009 Jul;103(1):14-25.
32. Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. Pharmacogenomics J. 2005;5(3):149-56. (Pubitemid 40852216)
33. Ingelman-Sundberg M, Gomez A. The past, present and future of pharmacoepigenomics. Pharmacogenomics. 2010 May;11(5):625-7.
34. Kacevska M, Ivanov M, Ingelman-Sundberg M. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin Pharmacol Ther. 2011 Jun;89(6):902-7.
35. Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C. ovel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 2003 Oct;307(1):117-28. (Pubitemid 37151897)
36. Saeki M, Saito Y, Jinno H, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Shirao K, Minami H, Ohtsu A, Yoshida T, Saijo N, Ozawa S, Sawada J. Three novel single nucleotide polymorphisms in UGT1A9. Drug Metab Pharmacokinet. 2003;18(2):146-9.
37. Takahashi H, Maruo Y, Mori A, Iwai M, Sato H, Takeuchi Y. Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase (UGT1A9). Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):131-6. (Pubitemid 352019722)
38. Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos. 2006 Jul;34(7):1220-8.
39. Kansaku F, Kumai T, Sasaki K, Yokozuka M, Shimizu M, Tateda T, Murayama N, Kobayashi S, Yamazaki H. Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGT1A9 genotype and patient age. Drug Metab Pharmacokinet. 2011;26(5):532-7.
40. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Mürdter TE, Roots I, Brockmöller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26. (Pubitemid 37311148)
41. Lang T, Klein K, Fischer J. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001 Jul;11(5):399-415. (Pubitemid 32656581)
42. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun. 1997 Oct 9;239(1):298-304. (Pubitemid 27480360)
43. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DTdiaphorase). Br J Cancer. 1997;75(1):69-75. (Pubitemid 27007275)